R&D at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's R&D?
- Ionis Pharmaceuticals (IONS) reported R&D of $228.9M in Q4 2025.
- How has Ionis Pharmaceuticals's R&D changed year-over-year?
- Ionis Pharmaceuticals's R&D increased by 1.6% year-over-year, from $225.38M to $228.9M.
- What is the long-term trend for Ionis Pharmaceuticals's R&D?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's R&D has grown at a 0.9% compound annual growth rate (CAGR), from $899.63M to $915.62M.
- What does R&D mean?
- Expenses dedicated to creating new products and improving existing ones.
- How do you interpret R&D?
- Higher spending indicates a commitment to long-term innovation, though it may temporarily reduce current profitability.
- How does R&D compare across companies?
- High R&D intensity is a hallmark of the pharmaceutical and biotechnology sectors compared to other industries.